# US 2013/0274251 A1 · 2-(2-phenylethenyl) 1,3-benzodiazepine compounds useful for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274251 A1
- Document ID: US20130274251A1
- Status: Published application
- Kind: A1
- Application number: 13/976,876
- Filed: 2011-12-27
- Published: 2013-10-17
- Earliest claimed: 2010-12-27
- Assignees: Novotyr Therapeutics Ltd.
- Inventors: Hadas Reuveni; Alexander Levitzki
- Web page: https://patentgrep.com/patent/US20130274251A1

## CPC

- C07D 279/08: condensed with carbocyclic rings or ring systems
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds of formula (1) acting as protein kinase (PK) and receptor kinase (RK) signaling modulators. The invention further provides methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as anti-cancer agents for preventions and treatments of PK- and RK-related disorders, in particular cancer. (I) wherein A is H or CN; Z is S, SO or S02; X1, X2, X3, X4, X5, Y1 and Y2 are each independently selected from H, halogen, alkyl, haloalkyl and OR1; and Y3 and Y4 are each OR1, wherein each R1 is independently H, C1-C4 alkyl, acyl, —(CH2CH20)n wherein n is an integer of 1 to 20, or a functional group that gives rise to hydroxyl upon hydrolysis.

## Claims

### Claim at position 1

-50. (canceled)

### Claim 51

A compound represented by the structure of formula 1:
wherein
A is H or CN;
Z is S, SO or SO2;
X1, X2, X3, X4, X5, Y1 and Y2 are each independently selected from H, halogen, alkyl, haloalkyl and OR1; and
Y3 and Y4 are each OR1, wherein each R1 is independently H, C1-C4 alkyl, acyl, —(CH2CH2O)n wherein n is an integer of 1 to 20, or a functional group that gives rise to hydroxyl upon hydrolysis,
including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.

### Claim 52 (depends on 51)

A compound according to claim 51, wherein A is H.

### Claim 53 (depends on 51)

A compound according to claim 51, wherein A is CN.

### Claim 54 (depends on 51)

A compound according to claim 51, wherein Z is S.

### Claim 55 (depends on 51)

A compound according to claim 51, wherein Z is SO2.

### Claim 56 (depends on 51)

A compound according to claim 51, wherein
at least one of X1, X2, X3, X4, Y1 and Y2 is a halogen: or
X1, X2, X3, and X4 are each H or a halogen; or
Y3 and Y4 are each OH; or
Y1 and Y2 are each OH.

### Claim 57 (depends on 51)

A compound according to claim 51, wherein
A is H, Z is S, Y3 and Y4 are each OH, and X1 is a halogen selected from Br and I; or
A is CN, Z is S, Y3 and Y4 are each OH, and X1 is a halogen selected from Br and I; or
A is H, Z is S, Y3 and Y4 are each OH, and X3 is a halogen selected from Br and I; or
A is H, Z is S, Y3 and Y4 are each OH, and X2 is a halogen selected from Br and I; or
A is H, Z is S, Y3 and Y4 are each OH, and X1 and X4 are each a halogen selected from Br and I; or
A is H, Z is SO2, Y3 and Y4 are each OH, and X1 is a halogen selected from Br and I; or
A is H, Z is SO2, Y3 and Y4 are each OH, and at least one of X1, X2, X3, X4, Y1 and Y2 is a halogen.

### Claim 58 (depends on 51)

A compound according to claim 51, wherein
X2 is H; or
X5 is H or alkyl.

### Claim 59 (depends on 51)

A compound according to claim 51, selected from the group consisting of:

### Claim 60 (depends on 51)

A pharmaceutical composition comprising a therapeutically effective amount a compound according to claim 51, and a pharmaceutically acceptable carrier or excipient.

### Claim 61 (depends on 51)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 51, in combination with at least one other anti-cancer agent, wherein the compound and the at least one other anti-cancer agent together provide a therapeutic anti-cancer effect which is at least additive.

### Claim 62 (depends on 61)

The pharmaceutical composition according to claim 61, wherein the compound and the at least one other anti-cancer agent together provide a synergistic therapeutic anti-cancer effect.

### Claim 63 (depends on 51)

A method of inhibiting signal transduction mediated by a protein kinase (PK), comprising the step of contacting a cell comprising said PK with a compound according to claim 51.

### Claim 64 (depends on 63)

The method according to claim 63, wherein the compound of formula (1) directly or indirectly interacts with, affects or inhibits said PK or a protein in said PK-mediated pathway.

### Claim 65 (depends on 64)

The method according to claim 64, wherein the protein kinase is a receptor protein tyrosine kinase (RTK) which is selected from the group consisting of: a platelet-derived growth factor receptor (PDGFR), a fibroblast growth factor receptor (FGFR), a hepatocyte growth factor receptor (HGFR), an insulin receptor, an insulin-like growth factor-1 receptor (IGF-1R), an epidermal growth factor receptor (EGFR), a nerve growth factor receptor (NGFR), a vascular endothelial growth factor receptor (VEGFR), and a macrophage colony stimulating factor (M-CSFR).

### Claim 66 (depends on 64)

The method according to claim 64, wherein the compound of formula (1) is an inhibitor of an insulin receptor or an insulin-like growth factor-1 receptor (IGF-1R), or wherein the compound of formula (1) directly or indirectly interacts with, affects or inhibits a substrate protein in the IGF-1R mediated pathway.

### Claim 67 (depends on 66)

The method according to claim 66, wherein the substrate protein is Insulin Receptor Substrate 1 (IRS1), Insulin Receptor Substrate 2 (IRS2), or a combination thereof, wherein said compound of formula (1) leads to any one or more of (i) dissociation of IRS1 or IRS2 from the cell membrane; (ii) phosphorylation of IRS1 or IRS2; or (iii) degradation of IRS1 or IRS2, in any order.

### Claim 68 (depends on 51)

A method for inhibiting, treating or preventing a protein kinase (PK) related disorder, or an insulin-like growth factor I receptor (IGF-1R), an insulin receptor substrate 1 (IRS1) or an insulin receptor substrate 2 (IRS2) signaling related disorder in a subject, comprising the step of administering to the subject a compound according to claim 51.

### Claim 69 (depends on 68)

The method according to claim 68, wherein the PK related disorder is a cell proliferative disorder, a fibrotic disorder, an inflammatory disorder or a metabolic disorder.

### Claim 70 (depends on 69)

The method according to claim 69, wherein the PK related disorder is cancer or psoriasis.

### Claim 71 (depends on 51)

A method of inhibiting cell proliferation comprising contacting the cell with a compound according to claim 51.

### Claim 72 (depends on 51)

A method of treating cancer selected from the group consisting of ovarian cancer, prostate cancer, breast cancer, skin cancer, melanoma, metastatic melanoma, colon cancer, lung cancer, pancreatic cancer, gastric cancer, bladder cancer, Ewing's sarcoma, osteosarcoma, glioblastoma, lymphoma, leukemia, multiple myeloma, head and neck cancer, brain cancer, kidney cancer, bone cancer, liver cancer, hepatocarcinoma and thyroid cancer in a subject comprising the step of administering to the subject a compound according to claim 51.
